Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.30 |
| ▸ | CSNK2A3 | Q8NEV1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059283 | 0.95 | KCNH2 (0.31) | TP53SMN1; SMN2 | |
| SCHEMBL4060056 | 0.90 | SIGMAR1 (0.30) | — | |
| SCHEMBL4058498 | 0.87 | TP53 (0.31) | TP53SMN1; SMN2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4069324 | 0.87 | TP53 (0.33) | TP53SMN1; SMN2 | |
| SCHEMBL4062100 | 0.84 | — | — | |
| SCHEMBL4059390 | 0.83 | CSNK2A2 (0.37) | CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL4059050 | 0.83 | KCNH2 (0.31) | TP53SMN1; SMN2 | |
| SCHEMBL4067455 | 0.82 | KCNH2 (0.32) | TP53SMN1; SMN2 | |
| SCHEMBL20357829 | 0.81 | CSNK2A2 (0.43) | CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL4063200 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | claimed |
| US-7569691-B2 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-08-04 | — | — | US | disclosed |
| EP-1714968-B1 | Protected piperazino group-bearing organoxysilane compound and making method | SHINETSU CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | SHIN-ETSU CHEMICAL CO., LTD. | 2006-10-26 | — | — | US | disclosed |
| EP-1714968-A1 | Protected piperazino group-bearing organoxysilane compound and making method | Shin-Etsu Chemical Co., Ltd. (JP) | 2006-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241294-A1 | Protected piperazino group-bearing organoxysilane compound and making method | PIEZO1, VCL, VIM | TP53 2897/4885SMN1; SMN2 1719/4885CSNK2A2 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.